Frost & Sullivan's recent analysis provides a detailed profile of the top 10 global biopharmaceutical companies, including the top five products and pipelines by development phase. In addition, the study projects that the market will reach over $300 billion by 2022 at a compound annual growth rate (CAGR) of close to 10 percent.
For further information on this analysis, please visit: http://frost.ly/286
"To keep up with the growing demand for new and advanced therapies, companies are either adopting hybrid business models or indulging in partnerships or acquisition activities to attain technology proficiency as well as specific therapy expertise," said Aarti Chitale, Transformational Health Senior Research Analyst at Frost & Sullivan. "As a result, virtual pharmaceutical companies are coming to the fore by collaborating with bigger pharmaceutical players and providing specific services to these partners in terms of drug discovery, development, or manufacturing."
Strategic imperatives for the global biologics companies include:
- Focusing on unmet needs by investing across the most promising segments, such as oncology, neurological disorders, infectious diseases, diabetes, and immunology among others, which have shown high acceptability across regions;
- Capturing investment opportunities by partnering with niche players;
- Forming strategic collaborations: Small-to-mid sized pharmaceutical companies are focusing on biologics discovery and development, by collaborating with larger pharmaceutical and generic manufacturers, contract development and manufacturing organizations (CDMOs) and Contract Research Organizations (CROs); and
- Adopting newer development and manufacturing techniques, including improvements in bioanalytical testing.
Global Biologics Market—Companies-to-Action is part of Frost & Sullivan's Transformational Health Growth Partnership Services program.
About Frost & SullivanFor over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion
Global Biologics Market—Companies-to-ActionMD83_52
Contact:Mariana FernandezCorporate Communications – North AmericaP: +1 (210) 348 1012E: [email protected]
http://ww2.frost.com
twitter: @FS_Healthcare
LinkedIn: Transform Health
View original content:http://www.prnewswire.com/news-releases/global-biologics-market-to-surpass-300-billion-by-2022-with-accelerated-new-launches-in-oncology-300619374.html
SOURCE Frost & Sullivan